Glial cells - The key elements of alzheimer´s disease

Current Alzheimer Research

Volumn 13, Issue 8, 2016, Pages 894-911

  Dzamba, David ^a,b   Harantova, Lenka ^a,b   Butenko, Olena ^a   Anderova, Miroslava ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer s disease; Astrocytes; Glial cells; Homeostasis; Microglia; NG2 glia; Oligodendrocytes; Therapy

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA CATENIN; BUNGAROTOXIN RECEPTOR; CALCIUM ION; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; EXCITATORY AMINO ACID TRANSPORTER; GELATINASE A; GELATINASE B; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE TRANSPORTER; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULINASE; INTERLEUKIN 13; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE METALLOENDOPEPTIDASE; NEUROTROPHIC FACTOR; PROTEIN; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

AGING; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; DISEASE COURSE; EFFECTOR CELL; EXCITOTOXICITY; GENE EXPRESSION; GLIA CELL; HUMAN; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY; ANIMAL; DRUG EFFECTS; GLIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; NEUROGLIA;

EID: 84975747879     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160129095924     Document Type: Article

References (201)

1. Alzheimer, Thies W, Bleiler L. 2012 Alzheimer’s disease facts and figures. Alzheimer’s Dement 8: 131-168 (2012).
2. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 342(8873): 710-711 (1993).
3. Thambisetty M, An Y, Tanaka T. Alzheimer’s disease risk genes and the age-at-onset phenotype. Neurobiol Aging 34(11): 2696.e1-5 (2013).
4. Spies PE, Slats D, Sjogren JMC, Kremer BPH, Verhey FRJ, Rikkert MGMO, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer's dementia. Curr Alzheimer Res 7(5): 470-476 (2010).
5. Welander H, Franberg J, Graff C, Sundstrom E, Winblad B, Tjernberg LO. Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110(2): 697-706 (2009).
6. Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352(6332): 239-241 (1991).
7. Mucke L, Masliah E, Johnson WB, Ruppe MD, Alford M, Rockenstein EM, et al. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res 666(2): 151-67 (1994).
8. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373(6514): 523-527 (1995).
9. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature 389(6651): 603-606 (1997).
10. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-102 (1996).
11. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94(24): 13287-13292 (1997).
12. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17(5): 1005-1013 (1996).
13. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276(24): 21562-21570 (2001).
14. Oddo S, Caccamo A, Shepherd J. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39(3): 409-421 (2003).
15. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging 24(8):1063-1070 (2003).
16. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24(35): 7707-7717 (2004).
17. Simon A-M, Schiapparelli L, Salazar-Colocho P, Cuadrado-Tejedor M, Escribano L, Lopez de Maturana R, et al. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol Dis 33(3): 369-378 (2009).
18. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer’s disease. J Biol Chem 270: 28257-28267 (1995).
19. Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 17(5): 661-663 (2014).
20. Drew SC, Masters CL, Barnham KJ. Alzheimer’s Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination. PLoS One 5(12): e15875 (2010).
21. Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, et al. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 183(2): 369-381 (2013).
22. Kalback W, Watson MD, Kokjohn TA, Kuo Y-M, Weiss N, Luehrs DC, et al. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer’s disease senile plaques. Biochemistry 41: 922-928 (2002).
23. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci 33(15): 6245-6256 (2013).
24. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11): 4050-4058 (2000).
25. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Aβ Plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One 8(4): e59586 (2013).
26. Fu Y, Rusznak Z, Kwok J, Kim WS, Paxinos G. Age-dependent alterations of the hippocampal cell composition and proliferative potential in the hAβPPSwInd-J20 mouse. J Alzheimers Dis 41(4): 1177-1192 (2014).
27. Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Exp Neurol 239: 28-37 (2013).
28. Pomilio C, Pavia P, Gorojod RM, Vinuesa A, Alaimo A, Galvan V, et al. Glial alterations from early to late stages in a model of Alzheimer’s disease: Evidence of autophagy involvement in Aβ internalization. Hippocampus 26(2): 194-210 (2016).
29. Song S-K, Kim JH, Lin S-J, Brendza RP, Holtzman DM. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol Dis 15(3): 640-647 (2004).
30. O’Hare E, Ardis T, Page D, Scopes DIC, Kim EM. AβPPoverexpressing transgenic rat model of Alzheimer’s disease utilizing the Tg2576 mouse protocol. J Alzheimers Dis 37: 77-88 (2013).
31. He P, Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer’s disease. J Neurosci 29: 6545-6557 (2009).
32. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2): 159-170 (2004).
33. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, Jansen AHP, et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7: e42823 (2012).
34. Li W, Tang Y, Fan Z, Meng Y, Yang G, Luo J, et al. Autophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide. Mol Neurodegener 8: 27 (2013).
35. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7(9): 940-946 (2006).
36. Delekate A, Fuchtemeier M, Schumacher T, Ulbrich C, Foddis M, Petzold GC. Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model. Nat Commun 5: 5422 (2014).
37. Mitew S, Kirkcaldie MTK, Dickson TC, Vickers JC. Altered synapses and gliotransmission in alzheimer’s disease and AD model mice. Neurobiol Aging 34: 2341-2351 (2013).
38. Jimenez S, Baglietto-Vargas D, Caballero C, Moreno-Gonzalez I, Torres M, Sanchez-Varo R, et al. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer’s disease: age-dependent switch in the microglial phenotype from alternative to classic. J Neurosci 28: 11650-11661 (2008).
39. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 8(4): e60921 (2013).
40. Behrendt G, Baer K, Buffo A, Curtis MA, Faull RL, Rees MI, et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 61(2): 273-286 (2013).
41. Behrendt M. Glial cell reactivity in mouse models reflecting different aspects of Alzheimer’s disease (2012).
42. Boda E, Vigano F, Rosa P, Fumagalli M, Labat-Gest V, Tempia F, et al. The GPR17 receptor in NG2 expressing cells: focus on in vivo cell maturation and participation in acute trauma and chronic damage. Glia 59: 1958-1973 (2011).
43. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5(1): 101-106 (1999).
44. Pak K, Chan SL, Mattson MP. Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice. Neuromol Med 3(1): 53-64 (2003).
45. Moon M, Cha MY, Mook-Jung I. Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFADl. J Alzheimer’s Dis 41: 233-241 (2014).
46. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40): 10129-10140 (2006).
47. Ou-Yang M-H, Van Nostrand WE. The absence of myelin basic protein promotes neuroinflammation and reduces amyloid β-protein accumulation in Tg-5xFAD mice. J Neuroinflamm 10: 134 (2013).
48. Yeh C-Y, Vadhwana B, Verkhratsky A, Rodriguez JJ. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer’s disease. ASN Neuro 3(5): 271-279 (2011).
49. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J Anat 221(3): 252-262 (2012).
50. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Agedependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: mechanism for deficient glutamatergic transmission? Mol Neurodegener 1750-1326-6-55 (2011).
51. Rodriguez JJ, Witton J, Olabarria M, Noristani HN, Verkhratsky A. Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer’s disease. Cell Death Dis 1:e1. (2010).
52. Rodriguez JJ, Noristani HN, Verkhratsky A. Microglial response to Alzheimer’s disease is differentially modulated by voluntary wheel running and enriched environments. Brain Struct Funct 220(2): 941-953 (2015).
53. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer’s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 57(1): 54-65 (2009).
54. Desai MK, Mastrangelo MA, Ryan DA, Sudol KL, Narrow WC, Bowers WJ. Early oligodendrocyte/myelin pathology in Alzheimer’s disease mice constitutes a novel therapeutic target. Am J Pathol 177(3): 1422-1435 (2010).
55. Hanisch U-K, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394 (2007).
56. Tremblay M-E, Zettel ML, Ison JR, Allen PD, Majewska AK. Effects of aging and sensory loss on glial cells in mouse visual and auditory cortices. Glia 60(4): 541-558 (2012).
57. Streit WJ, Xue Q-S. Life and death of microglia. J Neuroimmune Pharmacol 4(4): 371-379 (2009).
58. Hart AD, Wyttenbach A, Perry VH, Teeling JL. Age related changes in microglial phenotype vary between CNS regions: grey versus white matter differences. Brain Behav Immun 26(5): 754-765 (2012).
59. Luo X-G, Chen S-D. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener 1(1): 9 (2012).
60. Streit WJ, Braak H, Xue Q-S, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol 118(4): 475-485 (2009).
61. Deng X-H, Bertini G, Xu Y-Z, Yan Z, Bentivoglio M. Cytokineinduced activation of glial cells in the mouse brain is enhanced at an advanced age. Neuroscience 141(2): 645-661 (2006).
62. Marlatt MW, Bauer J, Aronica E, van Haastert ES, Hoozemans JJM, Joels M, et al. Proliferation in the Alzheimer hippocampus is due to microglia, not astroglia, and occurs at sites of amyloid deposition. Neural Plast 2014: 693851 (2014).
63. Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky R A, Frosch MP, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 72(6): 462-471 (2013).
64. Doorn KJ, Goudriaan A, Blits-Huizinga C, Bol JGJM, Rozemuller AJ, Hoogland PVJM, et al. Increased amoeboid microglial density in the olfactory bulb of Parkinson’s and Alzheimer's patients. Brain Pathol 24(2): 152-165 (2014).
65. Rodriguez JJ, Noristani HN, Hilditch T, Olabarria M, Yeh CY, Witton J, et al. Increased densities of resting and activated microglia in the dentate gyrus follow senile plaque formation in the CA1 subfield of the hippocampus in the triple transgenic model of Alzheimer’s disease. Neurosci Lett 552: 129-134 (2013).
66. Babcock AA, Ilkjar L, Clausen BH, Villadsen B, Dissing-Olesen L, Bendixen ATM, et al. Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. Brain Behav Immun 2015. doi:10.1016/j.bbi.2015.03.006.
67. Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-β fibrils. J Alzheimers Dis 26(5): 754-765 (2012).
68. Njie EG, Boelen E, Stassen FR, Steinbusch HWM, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging 33(1): 195.e1-12 (2012).
69. Chen J-H, Ke K-F, Lu J-H, Qiu Y-H, Peng Y-P. Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer’s disease model rats. PLoS One 10(2): e0116549 (2015).
70. Wilkinson K, El Khoury J. Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alzheimers Dis 2012: 489456 (2012).
71. Katsouri L, Georgopoulos S. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an alzheimer’s disease mouse model. PLoS One 6(7): e21880 (2011).
72. Lee M, McGeer E, McGeer PL. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer’s disease pathogenesis. Neurobiol Aging 36(1): 42-52 (2015).
73. Orre M, Kamphuis W, Osborn LM, Jansen AHP, Kooijman L, Bossers K, et al. Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction. Neurobiol Aging 35(12): 2746-2760 (2014).
74. Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ, et al. Reactive glia show increased immunoproteasome activity in Alzheimer’s disease. Brain 136(Pt 5): 1415-1431 (2013).
75. Solito E, Sastre M. Microglia function in Alzheimer’s disease. Front Pharmacol 3: 14 (2012).
76. Walker DG, Whetzel AM, Lue L-F. Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer’s disease brains and human microglia. Neuroscience 302: 121-137 (2015).
77. Torres KC, Lima GS, Fiamoncini CM, Rezende VB, Pereira PA, Bicalho MA, et al. Increased frequency of cluster of differentiation 14 (CD14+) monocytes expressing interleukin 1 beta (IL-1β) in Alzheimer’s disease patients and intermediate levels in late-onset depression patients. Int J Geriatr Psychiatry 29(2): 137-143 (2014).
78. Brawek B, Schwendele B, Riester K, Kohsaka S, Lerdkrai C, Liang Y, et al. Impairment of in vivo calcium signaling in amyloid plaque-associated microglia. Acta Neuropathol 127(4): 495-505 (2014).
79. Brawek B, Garaschuk O. Network-wide dysregulation of calcium homeostasis in Alzheimer’s disease. Cell Tissue Res 357(2): 427-438 (2014).
80. McLarnon JG, Choi HB, Lue L-F, Walker DG, Kim SU. Perturbations in calcium-mediated signal transduction in microglia from Alzheimer’s disease patients. J Neurosci Res 81(3): 426-435 (2005).
81. Jiang T, Tan L, Zhu X-C, Zhang Q-Q, Cao L, Tan M-S, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology 39(13): 2949-2962 (2014).
82. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22(1):183-192 (2002).
83. Halassa MM, Fellin T, Takano H, Dong J-H, Haydon PG. Synaptic islands defined by the territory of a single astrocyte. J Neurosci 27(24): 6473-6477 (2007).
84. Lind BL, Brazhe AR, Jessen SB, Tan FCC, Lauritzen MJ. Rapid stimulus-evoked astrocyte Ca2+ elevations and hemodynamic responses in mouse somatosensory cortex in vivo. Proc Natl Acad Sci USA 110: E4678-E4687 (2013).
85. Oberheim NA, Tian G-F, Han X, Peng W, Takano T, Ransom B, et al. Loss of astrocytic domain organization in the epileptic brain. J Neurosci 28: 3264-3276 (2008).
86. Verkhratsky A, Butt A. Glial neurobiology. USA: Wiley (2007).
87. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astrogliosis. J Neurosci 32: 6391-6410 (2012).
88. Barreto GE, Sun X, Xu L, Giffard RG. Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. PLoS One 6: e27881 (2011).
89. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia 58(7): 831-838 (2010).
90. Beauquis J, Vinuesa A, Pomilio C, Pavia P, Galvan V, Saravia F. Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer’s disease. Hippocampus 24(3): 257-269 (2014).
91. Senitz D, Reichenbach A, Smith TG. Surface complexity of human neocortical astrocytic cells: changes with development, aging, and dementia. J Hirnforsch 36(4): 531-537 (1995).
92. Colombo J., Quinn B, Puissant V. Disruption of astroglial interlaminar processes in Alzheimer’s disease. Brain Res Bull 2002. doi:10.1016/S0361-9230(02)00785-2.
93. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi E-J, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging 35(3): 492-510 (2014).
94. Serrano-Pozo A, Gomez-Isla T, Growdon JH, Frosch MP, Hyman BT. A phenotypic change but not proliferation underlies glial responses in Alzheimer disease. Am J Pathol (2013).
95. Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 31(4): 578-590 (2010).
96. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang H-Y. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 971(2): 197-209 (2003).
97. Luccarini I, Grossi C, Traini C, Fiorentini A, Ed Dami T, Casamenti F. Aβ plaque-associated glial reaction as a determinant of apoptotic neuronal death and cortical gliogenesis: a study in APP mutant mice.Aβ plaque-associated glial reaction as a determinant of apoptotic neuronal death and cortical gliogenesis: a study in APP. Neurosci Lett 506(1): 94-99 (2012).
98. Kamphuis W, Orre M, Kooijman L, Dahmen M, Hol EM. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer’s disease mouse model. Glia 2012 60(4): 615-629.
99. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012): 1774 (2010).
100. Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM. The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes. Exp Neurol 233(1): 373-379 (2012).
101. Pihlaja R, Koistinaho J, Kauppinen R, Sandholm J, Tanila H, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia 59(11): 1643-1657 (2011).
102. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9(4): 453-457 (2003).
103. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 25: 663-674 (2004).
104. Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 27(1):187-198 (2013).
105. Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol 179(3):1373-1384 (2011).
106. Saadoun S, Papadopoulos MC, Watanabe H, Yan D, Manley GT, Verkman AS. Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J Cell Sci 118(Pt 24): 5691-5698 (2005).
107. Yang W, Wu Q, Yuan C, Gao J, Xiao M, Gu M, et al. Aquaporin-4 mediates astrocyte response to β-amyloid. Mol Cell Neurosci 49(4): 406-414 (2012).
108. Wilcock D, Vitek M, Colton C. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer’s disease. Neuroscience 159(3): 1055-1069 (2009).
109. Dmytrenko L, Cicanic M, Anderova M, Vorisek I, Ottersen OP, Sykova E, et al. The impact of alpha-syntrophin deletion on the changes in tissue structure and extracellular diffusion associated with cell swelling under physiological and pathological conditions. PLoS One 8: e68044 (2013).
110. Anderova M, Benesova J, Mikesova M, Dzamba D, Honsa P, Kriska J, et al. Altered astrocytic swelling in the cortex of α-syntrophin-negative GFAP/EGFP mice. PLoS One 9(11): e113444 (2014).
111. Alarcon R, Fuenzalida C, Santibanez M, von Bernhardi R. Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surfacebound beta-amyloid. J Biol Chem 280(34): 30406-30415 (2005).
112. Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Lowdensity lipoprotein receptor represents an apolipoprotein Eindependent pathway of Aβ uptake and degradation by astrocytes. J Biol Chem 287(17): 13959-13971 (2012).
113. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA 110(19): E1807-E1816 (2013).
114. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10(7): 719-726 (2004).
115. Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R. Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 62(4): 493-503 (2014).
116. Li Y, Cheng D, Cheng R, Zhu X, Wan T, Liu J, et al. Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer’s disease amyloid-β proteins. PLoS One 62(4): 493-503 (2014).
117. Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, et al. Enhancing astrocytic lysosome biogenesis facilitates aβ clearance and attenuates amyloid plaque pathogenesis. J Neurosci 34(29): 9607-9620 (2014).
118. Kuchibhotla K, Lattarulo C, Hyman B, Bacskai B. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science 323(5918): 1211-1215 (2009).
119. Abramov AY, Canevari L, Duchen MR. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci 23(12):5088-5095 (2003).
120. Lasagna-Reeves CA, Kayed R. Astrocytes contain amyloid-β annular protofibrils in Alzheimer’s disease brains. FEBS Lett 585(19): 3052-3057 (2011).
121. Abramov AY, Ionov M, Pavlov E, Duchen MR. Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: implications for Alzheimer’s disease. Aging Cell 10(4): 595-603 (2011).
122. Kuchibhotla K, Goldman S, Lattarulo C. Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 59: 214-225 (2008).
123. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. Science 321(5896):1686-1689 (2008).
124. Bai J-Z, Lipski J. Involvement of TRPV4 channels in Aβ(40)-induced hippocampal cell death and astrocytic Ca(2+) signalling. Neurotoxicology 41: 64-72 (2014).
125. Alberdi E, Wyssenbach A, Alberdi M, Sanchez-Gomez M V, Cavaliere F, Rodriguez JJ, et al. Ca(2+)-dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid β-treated astrocytes and in a model of Alzheimer’s disease. Aging Cell 12(2): 292-302 (2013).
126. Agostinho P, Lopes JP, Velez Z, Oliveira CR. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int 52(6): 1226-1233 (2008).
127. Hudry E, Wu H-Y, Arbel-Ornath M, Hashimoto T, Matsouaka R, Fan Z, et al. Inhibition of the NFAT pathway alleviates amyloid β neurotoxicity in a mouse model of Alzheimer’s disease. J Neurosci 32(9): 3176-3192 (2012).
128. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong C-X. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 280(45): 37755-37762 (2005).
129. Lim D, Iyer A, Ronco V, Grolla AA, Canonico PL, Aronica E, et al. Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB. Glia 61(7): 1134-1145 (2013).
130. Grolla AA, Fakhfouri G, Balzaretti G, Marcello E, Gardoni F, Canonico PL, et al. Aβ leads to Ca2+ signaling alterations and transcriptional changes in glial cells. Neurobiol Aging 34(2): 511-522 (2013).
131. Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, Bachstetter AD, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease. J Neurosci 32(46): 16129-16140 (2012).
132. Le Prince G, Delaere P, Fages C, Lefrancois T, Touret M, Salanon M, et al. Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem Res 20: 859-862 (1995).
133. Robinson SR. Neuronal expression of glutamine synthetase in Alzheimer’s disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem Int 36: 471-482 (2000).
134. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimers Dis 11(1): 97-116 (2007).
135. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer’s disease. Neurobiol Aging 32(3): 553.e1-11 (2011).
136. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 69(7): 667-676 (2010).
137. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J Neurosci 33(12): 5312-5318 (2013).
138. Peters O, Schipke CG, Philipps A, Haas B, Pannasch U, Wang LP, et al. Astrocyte function is modified by Alzheimer’s disease-like pathology in aged mice. J Alzheimers Dis 18:177-189 (2009).
139. Yu W-F, Guan Z-Z, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer’s disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 192(1): 215-225 (2005).
140. Pirttimaki TM, Codadu NK, Awni A, Pratik P, Nagel DA, Hill EJ, et al. α7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Aβ effects in a preclinical Alzheimer’s mouse model. PLoS One 8(11): e81828 (2013).
141. Kamynina A V, Holmstrom KM, Koroev DO, Volpina OM, Abramov AY. Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against betaamyloid toxicity. Int J Biochem Cell Biol 45(4): 899-907 (2013).
142. Liu Y, Zeng X, Hui Y, Zhu C, Wu J, Taylor DH, et al. Activation of α7 nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: implications for Parkinson’s disease. Neuropharmacology 91: 87-96 (2015).
143. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68(3): 209-245 (2002).
144. Lee S, Yoon B-E, Berglund K, Oh S-J, Park H, Shin H-S, et al. Channel-mediated tonic GABA release from glia. Science 330: 790-796 (2010).
145. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med 20(8): 886-896 (2014).
146. Zhao J, O’Connor T, Vassar R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer’s disease pathogenesis. J Neuroinflamm 8: 150 (2011).
147. Ronco V, Grolla AA, Glasnov TN, Canonico PL, Verkhratsky A, Genazzani AA, et al. Differential deregulation of astrocytic calcium signalling by amyloid-β, TNFα, IL-1β and LPS. Cell Calc 55(4): 219-229 (2014).
148. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol 239: 133-138 (2013).
149. Severini C, Passeri PP, Ciotti M, Florenzano F, Possenti R, Zona C, et al. Bindarit, inhibitor of CCL2 synthesis, protects neurons against amyloid-β-induced toxicity. J Alzheimers Dis 38(2): 281-293 (2014).
150. Garwood CJ, Pooler a M, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2: e167 (2011).
151. Zaheer S, Thangavel R, Wu Y, Khan MM, Kempuraj D, Zaheer A. Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer’s disease mice. Neurochem Res 38(1): 218-225 (2013).
152. Sekar S, McDonald J, Cuyugan L, Aldrich J, Kurdoglu A, Adkins J, et al. Alzheimer’s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol Aging 36(2): 583-591 (2015).
153. Jiang T, Cadenas E. Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell 13(6): 1059-1067 (2014).
154. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 30(1): 211-221 (2010).
155. Gavillet M, Allaman I, Magistretti PJ. Modulation of astrocytic metabolic phenotype by proinflammatory cytokines. Glia 56(9): 975-989 (2008).
156. Power JHT, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, et al. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer’s disease pathology. Acta Neuropathol 115(6): 611-622 (2008).
157. He Y, Jackman NA, Thorn TL, Vought VE, Hewett SJ. Interleukin-1β protects astrocytes against oxidant-induced injury via an NF-κBDependent upregulation of glutathione synthesis. Glia 63(9): 1568-1580 (2015).
158. Chia LS, Thompson JE, Moscarello MA. Alteration of lipid-phase behavior in multiple sclerosis myelin revealed by wide-angle x-ray diffraction. Proc Natl Acad Sci USA 81(6): 1871-1874 (1984).
159. Malone MJ, Szoke MC. Neurochemical changes in white matter. Aged human brain and Alzheimer’s disease. Arch Neurol 42(11): 1063-1066 (1985).
160. Barber R, Scheltens P, Gholkar A, Ballard C, McKeith I, Ince P, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 67(1): 66-72 (1999).
161. Rose SE, Chen F, Chalk JB, Zelaya FO, Strugnell WE, Benson M, et al. Loss of connectivity in Alzheimer’s disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 69(4): 528-530 (2000).
162. Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol 60(3): 393-398 (2003).
163. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol Aging 25(1): 5-18 (2004).
164. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease. Neurobiol Aging 25(7): 843-851 (2004).
165. Bartzokis G, Lu PH, Mintz J. Human brain myelination and amyloid beta deposition in Alzheimer’s disease. Alzheimers Dement 3(2): 122-125 (2007).
166. Vlkolinsky R, Cairns N, Fountoulakis M, Lubec G. Decreased brain levels of 2’,3’-cyclic nucleotide-3'-phosphodiesterase in Down syndrome and Alzheimer's disease. Neurobiol Aging 22(4): 547-553 (2001).
167. Kobayashi K, Hayashi M, Nakano H, Fukutani Y, Sasaki K, Shimazaki M, et al. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer’s disease. Neuropathol Appl Neurobiol 28: 238-251 (2002).
168. Sjobeck M, Englund E. Glial levels determine severity of white matter disease in Alzheimer’s disease: a neuropathological study of glial changes. Neuropathol Appl Neurobiol 29(2): 159-169(2003).
169. Garcia-Ladona FJ, Huss Y, Frey P, Ghandour MS. Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: in situ hybridization and immunocytochemical detection. J Neurosci Res 50(1): 50-61 (1997).
170. Xu J, Chen S, Ahmed SH, Chen H, Ku G, Goldberg MP, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 21: RC118 (2001).
171. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta 1758(12): 2027-2036 (2006).
172. Lee J-T, Xu J, Lee J-M, Ku G, Han X, Yang D-I, et al. Amyloidbeta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164(1): 123-131 (2004).
173. Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J. Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced iNOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 94: 703-712 (2005).
174. Roth AD, Ramirez G, Alarcon R, Von Bernhardi R. Oligodendrocytes damage in Alzheimer’s disease: beta amyloid toxicity and inflammation. Biol Res 38: 381-387 (2005).
175. Chen S, Lee J-M, Zeng C, Chen H, Hsu CY, Xu J. Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J Neurochem 97: 631-640 (2006).
176. Horiuchi M, Maezawa I, Itoh A, Wakayama K, Jin L-W, Itoh T, et al. Amyloid β 1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol Aging 33(3): 499-509 (2012).
177. Nishimura M, Tomimoto H, Suenaga T, Namba Y, Ikeda K, Akiguchi I, et al. Immunocytochemical characterization of glial fibrillary tangles in Alzheimer’s disease brain. Am J Pathol 146(5): 1052-1058 (1995).
178. Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylases in Alzheimer’s disease. J Biol Chem 279(33): 34674-34678 (2004).
179. Honjo Y, Ayaki T, Tomiyama T, Horibe T, Ito H, Mori H, et al. Increased GADD34 in oligodendrocytes in Alzheimer’s disease. Neurosci Lett 602: 50-55 (2015).
180. Salins P, Shawesh S, He Y, Dibrov A, Kashour T, Arthur G, et al. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci Lett 412(3): 211-216 (2007).
181. Xu J-P, Zhao J, Li S. Roles of NG2 glial cells in diseases of the central nervous system. Neurosci Bull 27: 413-421 (2011).
182. Nielsen HM, Ek D, Avdic U, Orbjorn C, Hansson O, Veerhuis R, et al. NG2 cells, a new trail for Alzheimer’s disease mechanisms? Acta Neuropathol Commun 1: 7 (2013).
183. Li W, Tang Y, Fan Z, Meng Y, Yang G, Luo J, et al. Autophagy is involved in oligodendroglial precursor-mediated clearance of amyloid peptide. Mol Neurodegener 8: 27 (2013).
184. Kuljiš RO. The fourth element targeting hypothesis of Alzheimer’s disease pathogenesis and pathophysiology. Front Neurol 1: 144 (2010).
185. Lavoie S, Chen Y, Dalton TP, Gysin R, Cuenod M, Steullet P, et al. Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J Neurochem 108(6): 1410-1422 (2009).
186. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol (2008).
187. Oliva CA, Vargas JY, Inestrosa NC. Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci (2013).
188. Inestrosa N, De Ferrari G V, Garrido JL, Alvarez A, Olivares GH, Barria MI, et al. Wnt signaling involvement in beta-amyloiddependent neurodegeneration. Neurochem Int 41: 341-344 (2002).
189. Desai MK, Guercio BJ, Narrow WC, Bowers WJ. An Alzheimer’s disease-relevant presenilin-1 mutation augments amyloid-betainduced oligodendrocyte dysfunction. Glia 59: 627-640 (2011).
190. Malm TM, Iivonen H, Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Kanninen K, et al. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden. J Neurosci 27(14): 3712-3721 (2007).
191. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry 15(3): 272-285 (2010).
192. Halleskog C, Mulder J, Dahlstrom J, Mackie K, Hortobagyi T, Tanila H, et al. WNT signaling in activated microglia is proinflammatory. Glia 59(1): 119-131 (2011).
193. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller F-J, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106(32): 13594-13599 (2009).
194. Corbett GT, Roy A, Pahan K. Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for Alzheimer disease therapy. J Biol Chem 288(12): 8299-8312 (2013).
195. Revilla S, Ursulet S, Alvarez-Lopez MJ, Castro-Freire M, Perpina U, Garcia-Mesa Y, et al. Lenti-GDNF gene therapy protects against Alzheimer’s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 20(11): 961-972 (2014).
196. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer’s disease. Cell Calc 34(4-5): 385-397 (2003).
197. Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR. Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. Neuroreport 12: 1151-1154 (2001).
198. Rossner S, Apelt J, Schliebs R, Perez-Polo JR, Bigl V. Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res 64(5): 437-446 (2001).
199. Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, et al. Astrocytic expression of the Alzheimer’s disease beta-secretase (BACE1) is stimulus-dependent. Glia 41(2): 169-179 (2003).
200. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflamm 2: 22 (2005).
201. Chen J. SIRT1 Protects against Microglia-dependent Amyloid-Toxicity through Inhibiting NF-B Signaling. J Biol Chem 280: 40364-40374 (2005).